CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by JPMorgan Chase & Co.

CytomX Therapeutics (NASDAQ:CTMX) was upgraded by research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage presently has a $12.00 price target on the biotechnology company’s stock, up from their previous price target of $7.00. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 120.18% from the company’s current price.

Several other analysts have also weighed in on CTMX. Cantor Fitzgerald upped their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Barclays raised their target price on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Piper Sandler upped their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Finally, Guggenheim reiterated a “buy” rating and set a $10.00 price objective on shares of CytomX Therapeutics in a research report on Monday, March 9th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

CytomX Therapeutics Stock Down 19.3%

Shares of NASDAQ CTMX opened at $5.45 on Monday. CytomX Therapeutics has a 52-week low of $0.40 and a 52-week high of $8.21. The stock’s 50 day moving average price is $5.26 and its two-hundred day moving average price is $4.09. The stock has a market capitalization of $923.39 million, a P/E ratio of -136.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 20.65%. The company had revenue of $0.66 million for the quarter, compared to the consensus estimate of $7.33 million. On average, analysts anticipate that CytomX Therapeutics will post -0.05 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC bought a new position in shares of CytomX Therapeutics during the 3rd quarter valued at $25,000. Wells Fargo & Company MN boosted its holdings in CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares in the last quarter. Invesco Ltd. acquired a new position in CytomX Therapeutics during the second quarter worth $32,000. Pursue Wealth Partners LLC bought a new position in CytomX Therapeutics during the second quarter valued at about $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of CytomX Therapeutics during the 3rd quarter worth about $34,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 Varseta‑M expansion showed meaningful activity in heavily pretreated metastatic colorectal cancer (32% response rate at 10 mg/kg Q3W; estimated PFS ~7.1 months) with a manageable safety profile and planned FDA discussions to align on potential registrational trial — this is the primary catalyst for the earlier rally. Read More.
• Positive Sentiment: Multiple firms upgraded or raised price targets after the data (examples: Wedbush, HC Wainwright, JPMorgan noted higher PTs and upgraded ratings), which amplified buying interest and momentum. Read More.
• Neutral Sentiment: Company released its Q4 materials, slide deck and hosted an earnings call discussing the clinical progress and next‑steps (including combination studies and timelines) — useful context for longer‑term investors assessing pathway to a registrational study. Read More.
• Negative Sentiment: CytomX filed for an underwritten public offering to raise $250M (common stock and pre‑funded warrants) — a near‑term dilution risk that likely pressured the stock after the initial data‑driven surge. Read More.
• Negative Sentiment: Q4 results missed expectations (EPS and revenue; EPS -$0.22 vs. est. -$0.08; revenue ~$0.66M vs. est. ~$7.33M), which reinforces near‑term funding needs and contributed to selling pressure. Read More.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.